超治疗药物浓度触发信号:一种评估重症监护用药安全监测价值的数据驱动新方法
本研究利用荷兰14个ICU的电子健康记录数据,纳入6006例有治疗药物监测的成人ICU住院患者,评估电子超治疗药物浓度触发信号(eSDCT)与ICU结局的关联。49.5%的住院至少触发一种eSDCT,暴露者医院死亡率、ICU死亡率和ICU住院时间均更高;调整后抗生素和免疫抑制药eSDCT仍与不良结局相关,支持其用于ICU用药安全监测。
要点
- 抗生素和免疫抑制药eSDCT与ICU死亡率、医院死亡率及ICU住院时间延长独立相关。
- 数据驱动方法可快速评估eSDCT与患者结局关联,替代耗时的人工病历审查。
- eSDCT可作为ICU层面用药安全监测的筛查信号,支持其临床实施。
核心结论
- 抗生素和免疫抑制药eSDCT与ICU患者更差结局相关,支持其用于ICU用药安全监测。
研究设计与样本
- 基于荷兰14个ICU 2010-2020年成人电子健康记录数据的回顾性队列分析,纳入6006例有治疗药物监测的ICU住院。
- 采用调整的线性与逻辑混合效应模型评估eSDCT与ICU住院时间、ICU死亡率和医院死亡率的关联。
主要发现
- 6006例ICU住院中49.5%(n=2973)至少触发五种组水平eSDCT之一。
- 暴露者医院死亡率38.2% vs 27.9%,ICU死亡率30.6% vs 20.3%,ICU住院时间中位13.8天(IQR 5.6-28.1)vs 7.5天(IQR 3.2-15.7)。
- 调整后抗生素eSDCT与ICU死亡率OR 1.47(1.26-1.70)、医院死亡率OR 1.46(1.27-1.68)及ICU住院时间expB 1.82(1.71-1.94)相关。
- 调整后免疫抑制药eSDCT与ICU死亡率OR 2.86(1.56-5.24)、医院死亡率OR 1.81(1.07-3.10)及ICU住院时间expB 2.99(2.46-3.62)相关。
临床怎么用
- 可将抗生素和免疫抑制药超治疗浓度eSDCT作为ICU用药安全监测的筛查信号,优先人工复核。
- eSDCT关联结局数据可辅助快速评估触发信号临床价值,减少全面人工审查负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Electronic triggers (e-triggers) are used as screening signals to detect potential adverse drug events (ADEs) and offer an effective system level approach for medication safety surveillance. Their clinical utility is typically evaluated through time-consuming manual chart review by experts, limiting implementation. Estimating associations between e-triggers and relevant ICU patient outcomes may provide a rapid, data-driven alternative. In this study, electronic supratherapeutic drug concentration triggers (eSDCT) were used as a use case. METHODS: Pseudonymized Electronic Health Record (EHR) data from adults admitted to 14 Dutch ICUs (2010-2020) were analysed. Patients with ≥1 therapeutic drug monitoring measurements were included. eSDCTs were selected based on literature, data availability and expert input. Associations with ICU Length of Stay (LOS), ICU mortality and hospital mortality were assessed using adjusted linear and logistic mixed-effects models. RESULTS: Among 6006 ICU admissions, 49.5% (n = 2973) had ≥1 of the five selected group-level eSDCTs. Exposed admissions showed higher hospital mortality (38.2% vs. 27.9%), ICU mortality (30.6% vs. 20.3%) and longer ICU LOS (median 13.8 [IQR 5.6-28.1] vs. 7.5 [3.2-15.7] days) compared with unexposed admissions. After adjustment, antibiotic and immunosuppressive eSDCTs remained associated with increased ICU mortality (OR 1.47 [1.26-1.70] and 2.86 [1.56-5.24]), hospital mortality (OR 1.46 [1.27-1.68] and 1.81 [1.07-3.10]) and prolonged ICU LOS (expB 1.82 [1.71-1.94] and 2.99 [2.46-3.62]). CONCLUSION: Our data-driven approach shows that antibiotic and immunosuppressive eSDCTs are associated with worse ICU patient outcomes, supporting their implementation for ICU-level medication safety surveillance.
引用
- Langermans AP, Yasrebi-de Kom IAR, de Lange DW, et al. Supratherapeutic drug concentration triggers: A novel data-driven approach to assess their value for medication safety surveillance in intensive care. Br J Clin Pharmacol. 2026. PMID: 42165122. doi:10.1002/bcp.70610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。